Abstract
BACKGROUND: The red cell distribution width-to-albumin ratio (RAR) is an emerging prognostic indicator. However, its correlation with clinical endpoints in individuals with sepsis-associated acute respiratory distress syndrome (SA-ARDS) remains unclear. This study examined the relationship between RAR and all-cause mortality (ACM) in the intensive care unit (ICU) patients with SA-ARDS using the MIMIC-IV database. The goal was to identify high-risk individuals early on and improve prognostic assessment. METHODS: Analyses were conducted using data from the MIMIC-IV (V3.1) database. Adult patients who met Sepsis-3 criteria and the Berlin definition of ARDS were included. The outcomes were 30-, 90-, 180-, and 365-day mortality following ICU admission. Kaplan-Meier (KM) curves were utilized to estimate survival at corresponding timepoints. Cox regression was utilized to evaluate the association between RAR and mortality risk, including subgroup analyses. Restricted cubic spline (RCS) regression was adopted to explore the nonlinear correlation of RAR with ACM and to identify a possible cutoff value. Receiver operating characteristic (ROC) curves were applied for quantifying RAR’s predictive ability. Propensity score matching (PSM) was used to validate the findings. RESULTS: The current study included 6,042 patients. The first, median, and third quartiles of RAR were 4.14, 5.07, and 6.32, respectively. KM analysis revealed a significantly higher mortality risk in patients with high RAR (P < 0.001). Multivariable Cox regression analysis indicated an independent positive correlation of RAR with ACM. RCS curves revealed a nonlinear relationship (inflection point at 5.04). The areas under the curve (AUCs) for RAR predicting 30-, 90-, 180-, and 365-day mortality were 0.634, 0.648, 0.652, and 0.649, respectively. Subgroup analyses supported the association of RAR. PSM confirmed the robustness of these results. CONCLUSIONS: RAR was found to be independently associated with an increased 30-, 90-, 180-, and 365-day ACM in ICU patients with SA-ARDS. RAR may have potential value as an early indicator for identifying high‑risk ICU populations. CLINICAL TRIAL NUMBER: Not applicable. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12879-026-12827-4.